PTC Therapeutics files Form 144 for minor 2.5K-share insider sale

Rhea-AI Filing Summary

PTC Therapeutics, Inc. (PTCT) filed a Form 144 signaling an affiliate’s intent to sell up to 2,516 common shares through Fidelity Brokerage Services on or about 15 July 2025. The shares were recently acquired via restricted-stock vesting on 14 July 2025 and have an aggregate market value of approximately $124,435, implying a reference price near $49.45 per share. With 79.26 million shares outstanding, the planned disposition represents less than 0.01 % of total equity—too small to affect liquidity, control, or valuation. No additional sales by this insider have occurred within the past three months, and the filing provides no further operational or financial commentary.

Insights

Securities Analyst

TL;DR: Minor insider sale (<0.01 % float) — neutral signal, but worth monitoring for selling patterns.

The Form 144 covers only 2,516 shares worth roughly $124k, an immaterial fraction of PTCT’s capitalization. Such routine sales often stem from tax-related liquidity needs after restricted-stock vesting rather than negative views on fundamentals. No prior sales in the last quarter reduce concerns about systematic unloading. Still, persistent filings of this nature could foreshadow broader insider sentiment, so investors may track subsequent Forms 4 for confirmation. Overall impact on valuation, liquidity, or governance is negligible; rating remains neutral.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	2516	124435.07	79257019	07/15/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/14/2025	Restricted Stock Vesting	Issuer			2516	07/14/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does PTC Therapeutics' (PTCT) latest Form 144 disclose?

The filing shows an insider plans to sell 2,516 common shares valued at about $124,435 on or around 15 July 2025.

How significant is the 2,516-share sale relative to PTCT's float?

It equals less than 0.01 % of the company’s 79.26 million shares outstanding—financially immaterial.

When were the shares being sold by the insider acquired?

They vested as restricted stock on 14 July 2025 and were received as compensation.

Has the same insider sold PTCT shares in the last three months?

No; the filing reports "Nothing to Report" for prior 3-month sales.

Which broker will execute the proposed sale?

The shares are slated to be sold through Fidelity Brokerage Services LLC.